公开(公告)号：US20200150457A1

公开(公告)日：2020-05-14

申请号：US16561776

申请日：2019-09-05

Applicant: TSUBOTA LABORATORY, INC.

Inventor： Shinichi IKEDA ,  Xiaoyan JIANG ,  Kazuo TSUBOTA ,  Toshihide KURIHARA

IPC: G02C7/06 ,  A01K67/02 ,  A61K31/575 ,  A61K9/00

Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

公开(公告)号：US20240210736A1

公开(公告)日：2024-06-27

申请号：US18600985

申请日：2024-03-11

Applicant: TSUBOTA LABORATORY, INC.

Inventor： Shinichi IKEDA ,  Xiaoyan JIANG ,  Kazuo TSUBOTA ,  Toshihide KURIHARA

IPC: G02C7/06 ,  A01K67/02 ,  A61K9/00 ,  A61K31/575

CPC classification number: G02C7/06 ,  A01K67/02 ,  A61K9/0048 ,  A61K31/575 ,  A01K2227/105 ,  A01K2267/03

Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

公开(公告)号：US20230364441A1

公开(公告)日：2023-11-16

申请号：US18026232

申请日：2021-09-16

Applicant: TSUBOTA LABORATORY, INC.

Inventor： Xiaoyan JIANG ,  Kiwako MORI ,  Toshihide KURIHARA ,  Kazuo TSUBOTA

IPC: A61N5/06

CPC classification number: A61N5/0613 ,  A61N2005/0663

Abstract: A device and a method for inhibiting thinning of a choroid. A choroidal thinning inhibiting device including a light source that emits violet light having a wavelength within a range from 360 nm to 400 nm, the choroidal thinning inhibiting device inhibiting thinning of a choroid by irradiation with the violet light. This device may further include a control mechanism that controls an irradiance and an irradiation time of the violet light, can be applied to ocular diseases selected from age-related macular degeneration, glaucoma, diabetic retinopathy, macular edema, eye strain, retinal vascular occlusion, triangle syndrome, central serous chorioretinopathy, retinitis pigmentosa, presbyopia, cataracts, and the like that are based on inadequate blood flow or reduced blood flow, and can be expected to prevent and treat such ocular diseases.